Bausch+Lomb Results Presentation Deck
Total Bausch + Lomb P&L¹ (GAAP)
Bausch + Lomb
Vision Care Revenue
Surgical Revenue
Ophthalmic Pharmaceuticals Revenue
Total Revenue
Gross Profit
Gross Margin
R&D
R&D percent of Revenues
SG&A
SG&A percent of Revenues
Operating Income
Depreciation
Stock Based Compensation
Net (Loss) Income Attributable to
Bausch+Lomb
Net Income Margin
EPS³ Attributable to Bausch + Lomb
4Q22
$626M
$188M
$182M
$996M
$520M
52.2%
$78M
7.8%
BAUSCH + LOMB 3.4Q21 presented on an adjusted basis after giving effect to the IPO.
$386M
38.8%
$51M
$37M
$17M
($1M)
(0.1%)
($0.00)
4Q21
$626M
$198M
$177M
$1,001 M
$530M
52.9%
$70M
7.0%
$365M
36.5%
$92M
$33M
$17M
$51M
5.1%
$0.15
1. Products with sales outside the United States impacted by F/X changes.
2. This is a non-GAAP measure or ratio. See Slide 2 and Appendix for further information on non-GAAP measures and ratios.
Reported Change
4. Organic revenue growth/change, a non-GAAP measure, is defined as change on a period-over-period basis in revenues on a constant currency basis (if
applicable) excluding the impact of acquisitions, divestitures and discontinuations.
0%
(5%)
3%
0%
(2%)
(70 bps)
(11%)
(6%)
(45%)
12%
0%
(102%)
Constant Currency²
5%
2%
7%
5%
3%
(14%)
(11%)
(37%)
18%
0%
(90%)
Organic Change 2,4
5%
4%
7%
5%
12View entire presentation